The Scientific Advisory Board is made up of leaders in the fields of medical genetics, genomics and bioinformatics. The board will advise and assist in scientific research and product development initiatives focused on clinical applications.
Scientific Advisory Board
Sherri Bale, Ph.D., FACMGManaging Director and Co-founder, GeneDX; Senior Vice President, BioReference Laboratories; Founding Member of the American College of Medical Genetics
Sherri Bale received her BA in Biology from Clark University, her M.S. and Ph.D. degrees from the University of Pittsburgh, and her post-doctoral training in medical genetics at the National Institutes of Health, Bethesda, MD. She is an ABMG Board-Certified Ph.D.- Medical Geneticist and Founding Member of the American College of Medical Genetics, served on the ACMG Professional Practice and Guidelines Committee, the ACMG Foundation Committee, the Corporate Responsibility Task Force, co-chaired the Whole Exome//Genome Sequencing Task Force, and works with the Laboratory Practice Committee. She is a consultant to various academic, federal, and private organizations regarding clinical, technical, and regulatory issues in genetics and genetic testing. She co-founded GeneDx in 2000 after 16 years at the National Institutes of Health. GeneDx was acquired by BioReference Laboratories, Inc. in 2006. Dr. Bale served as President and Clinical Director of GeneDx until 2011, and then became Managing Director of GeneDx and Sr. Vice President of BioReference Laboratories. The company specializes in developing and providing molecular diagnostic tests for hereditary genetic disease using innovative methods. Dr. Bale has authored 140 peer-reviewed papers, book chapters, and books in the field of genetics. She serves as President of the Board of Directors of an international adoption agency that specializes in placing older and special needs children. She holds a second degree black belt in judo.
Hakon Hakonarson, M.D., Ph.D.Director of the Center for Applied Genomics; Associate Professor of Pediatrics, The Perelman School of Medicine, University of Pennsylvania.
Hakon Hakonarson is director of the Center for Applied Genomics and is also an associate professor of pediatrics at The Perelman School of Medicine of The University of Pennsylvania. He leads a $40 million commitment from The Children’s Hospital of Philadelphia (CHOP) to genotype approximately 100,000 children, an initiative that has gained nationwide attention in the Wall Street Journal, New York Times, Time Magazine, Nature and Science.
Dr. Hakonarson has previously held several senior posts within the biopharmaceutical industry, directing a number of genomics and pharmacogenomics projects as vice president of Clinical Sciences and Development at deCODE genetics, Inc. Dr. Hakonarson is the principal investigator (PI) on several National Institute of Health-sponsored grants, including Neurodevelopmental Genomics: Trajectories of Complex Phenotypes, the largest project ever supported by the National Institute of Mental Health. He has published numerous high-impact papers on genomic discoveries and their translations in some of the most prestigious scientific medical journals, including Nature, Nature Genetics and The New England Journal of Medicine. Time Magazine listed Dr. Hakonarson’s autism gene discovery project, reported in Nature in 2009, among the top 10 medical breakthroughs of that year. With over 15 years of experience in pioneering genomics research and genome-wide mapping and association studies, Dr. Hakonarson has intimate knowledge of the complexities of large-scale genomics projects and has put together the necessary infrastructure and workflow processes to unravel these complexities.
Madhuri Hegde, Ph.D., FACMGProfessor, Executive Director, Emory Genetics Laboratory, Department of Human Genetics, Emory University School of Medicine.
Madhuri Hegde is Professor, Department of Human Genetics at the Emory University School of Medicine and the Executive Director of the Emory Genetics Laboratory. Dr. Hegde has been a Member of Clinical Advisory Board at RainDance Inc, Tessarae Inc., and OGT, UK. The primary focus of Dr. Hegde's clinical work is the development of high-throughput sequencing strategies for rare disorders using sequence capture technologies, robotics, next-generation sequencing, oligonucleotide array platforms, robotics and using predictive analysis tools and biological testing. Her research focuses on functional analysis of sequence variants in disease associated genes, specifically muscular dystrophies, and translating what is learned in the basic research laboratory to clinical practice.
Eric Schadt, Ph.D.Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences and the Jean C. and James W. Crystal Professor of Genomics.
Eric Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. He has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease, which have been widely published in leading scientific journals. Dr. Schadt founded the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai in 2011, which now hosts 12 faculty members and roughly 150 staff and research scientists dedicated to the mission of better diagnosing and treating patients using advanced predictive models of disease.
Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Pacific Biosciences in 2009 as the Chief Scientific Officer, he was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics and his Ph.D. in bio-mathematics from University of California, Los Angeles.